LONDON – U.K. bioscience is due for a huge injection of cash after the technology commercialization arm of the Medical Research Council, Lifearc, sold off a portion of its future royalty stream to Merck & Co. Inc.'s Keytruda (pembrolizumab) for $1.297 billion.